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Abstract (270 words) 
Background:  Antineoplastic drugs for cancer are often associated with adverse events, which 
influence patients’ physical health, quality of life and survival. However, the modelling of 
adverse events in cost effectiveness analyses of antineoplastic drugs has not been examined.  
Aims:  This article reviews published economic evaluations which include a calculated cost for 
adverse events of antineoplastic drugs.  The aim is to identify how existing models manage four 
issues specific to antineoplastic drug adverse events: the selection of adverse events for inclusion 
in models, the influence of dose modifications on drug quantity and survival outcomes, the 
influence of adverse events on quality of life, and the consideration of multiple simultaneous or 
recurring adverse events.    
Methods:  A systematic literature search was conducted using MESH headings and key words in 
multiple electronic databases, covering the years 1999 to 2009.  Inclusion criteria for eligibility 
were papers covering a population of adults with solid tumour cancers, the inclusion of at least 
one adverse event, and the resource use and / or costs of adverse event treatment.   
Results:  From 4985 citations, 26 eligible articles were identified.  Studies were generally of 
moderate quality and addressed a range of cancers and treatment types.  While the four issues 
specific to antineoplastic drug adverse events were addressed by some studies, no study 
addressed all of the issues in the same model.   
Conclusion:  This review indicates that current modelling assumptions may restrict our 
understanding of the true impact of adverse events on cost effectiveness of antineoplastic drugs.  
This understanding could be improved through consideration of the selection of adverse events, 
dose modifications, multiple events and quality of life in cost effectiveness studies.   
 
Key points for decision makers 
 Current models of antineoplastic drug cost effectiveness may underestimate the 
incidence, cost and flow on effects of adverse events. 
 Decision makers should examine whether issues such as the selection of adverse events 
for inclusion, the implications of dose modifications, the impact of adverse events on 
quality of life, and the potential for multiple adverse events have been considered in 
models of antineoplastic drug cost effectiveness. 
 Models that address all of these issues relating to adverse events are feasible, and would 






Antineoplastic drugs, which include chemotherapy, are a common cancer treatment.  In 2007-08 
there were 260,000 separations for chemotherapy in Australian public and private hospitals 
combined [1].  However, antineoplastic drugs cause adverse events (side effects).  More than  
750 adverse events are listed in the National Cancer Institute’s Common Terminology Criteria 
for Adverse Events (NCI CTCAE) which is used to define and grade the seriousness of adverse 
events associated with cancer treatments [2].  Adverse events have been estimated to contribute 
up to 60% of the total cost of chemotherapy [3].   
Willingness to pay for cancer treatments in the community is high, due to a widespread public  
perception of cancer as a hidden and feared disease [4, 5].  This may lead to a ‘treat at all costs’ 
attitude with little consideration given to  the economic impacts of these treatments [4, 5].  
Economic evaluation is increasingly used to provide information to decision makers in the health 
care system about the relative value of alternative treatment strategies [4].  While such 
evaluations can be conducted as part of a clinical trial, economic modelling is often used to 
estimate costs and benefits in the longer term and to take into account different endpoints and 
comparators [6].   
Economic evaluation requires consideration of both the costs and benefits of a treatment, with 
data used to populate these costs and benefits in the model referred to as inputs.  Typically, 
antineoplastic drugs include three broad cost components – purchasing the antineoplastic 
products, time and resources for administration of the drugs, and managing adverse events.  On 
the benefit side, disease outcomes such as cancer progression and survival are commonly 
measured, with quality of life measurement required for cost utility analyses.  Inputs to economic 
evaluations for antineoplastic drug outcomes are often readily available through clinical trials, 
while product purchase costs can be obtained from pricing lists.  Less information is available 
estimating the costs of administration [7] and adverse events related to antineoplastic drugs [8]. 
There are a number of issues which are specific to the adverse events of antineoplastic drugs, 
that need to be considered in economic evaluations. 
Adverse event selection 
The inclusion of adverse events in models of antineoplastic drugs is important as these events 
can influence both sides of the economic evaluation equation.  Many economic evaluations of 
antineoplastic drugs are conducted for the purpose of reimbursement.  In this case awareness of 
the cost-effectiveness threshold is important, as well as the impact of model structure and inputs.  
The equal treatment of both arms is critical, and all relevant costs and consequences need to be 





As well as incurring a cost to manage the adverse event itself, the experience of an adverse event 
changes the way a patient receives antineoplastic therapy.  In many cases, when a patient 
experiences an adverse event, their drug dose is either delayed or the dose reduced until they 
have recovered from the adverse event [9].  The antineoplastic treatment may then continue at 
the reduced dose to lessen the chance of the adverse event re-occurring [9].  This influences the 
total amount of antineoplastic drug the patient receives [10], and therefore the amount of product 
purchased.   
The amount of an antineoplastic drug received by a patient can also impact on the outcomes of 
their treatment.  The relative dose intensity of chemotherapy is the ratio of the delivered 
chemotherapy to the planned chemotherapy dose over a specified period of time [11].  There is 
evidence that patients who receive a relative dose intensity of less than 85% have significant 
reductions in survival [10, 12-18].  Retrospective studies have found that up to 56% of people 
have a relative dose intensity less than 85% due to dose adjustments in response to adverse 
events [19].   
Adverse events and quality of life 
While adverse events differ between individuals, almost all patients on antineoplastic drugs will 
experience at least one adverse event [20].  Many patients report adverse events to be very 
distressing, with quality of life significantly impacted [21-23]. It is therefore important to 
consider that there may be additional utility decrements associated with having an adverse event, 
in addition to those already associated with having cancer and receiving antineoplastic therapy.   
Multiple adverse events 
The final consideration when including antineoplastic drug related adverse events in economic 
evaluation models is that of multiple events.  Patients may experience multiple adverse events in 
two ways – either the same event occurring multiple times over a course of antineoplastic 
therapy, or different adverse events happening simultaneously.  If a patient experiences the same 
event repeatedly, the management of the adverse event in terms of prevention, treatment and 
dose modifications may change, resulting in different costs and outcomes for the model [9].  The 
occurrence of more than one adverse event at the same time impacts on the management of each 
adverse event in terms of treatment, prevention and antineoplastic drug dose [9], and may also 
change the quality of life impact of an event.    
While there are generic guidelines for the development of economic evaluation models [24], 
these do not consider cancer-specific issues which may bias results [8].  A review of methods 
used for cost effectiveness analysis of cancer treatments found common problems in the areas of 
defining the decision problem, choosing the health outcomes, modelling effectiveness of 
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different types of treatment, modelling quality of life, modelling resource use including adverse 
events, discounting and assessing uncertainty [8].   However, the authors are unaware of any 
published reviews of the modelling techniques used specifically for evaluating the costs and 
consequences of adverse events associated with antineoplastic drugs.   
Adverse events have the potential to have a significant impact on models of antineoplastic drug 
cost effectiveness through not only the cost of managing the event itself, but also in terms of the 
quantity of antineoplastic products used, patient quality of life, and survival outcomes.  It is 
therefore important that adverse events be taken into account when conducting economic 
evaluations of antineoplastic drugs to ensure accurate estimates of cost effectiveness are 
obtained.   
1.1 Aim 
This article reviews published economic evaluations which include a method for determining 
resource use and/or have a method for calculating a cost for adverse events of antineoplastic 
drugs, to identify how these existing models manage potentially problematic areas specific to 
antineoplastic drug adverse events.  The primary areas of interest are model structure and inputs 
related to: 
 The selection of adverse events for inclusion in models  
 The influence of dose modifications 
o on antineoplastic drug product quantity 
o on survival outcomes 
 The influence of adverse events on quality of life 
 The influence of multiple adverse events, including 
o the same event occurring multiple times during a course of antineoplastic drug 
therapy 
o multiple events occurring at the same point in time. 
2. Methods 
A systematic literature search was conducted to identify relevant papers reporting research 
involving modelling the cost of antineoplastic drug adverse events.  Inclusion criteria for 
eligibility were papers covering a population of adults with solid tumour cancers, the inclusion of 
at least one antineoplastic drug related adverse event, the resource use and/or calculated costs of 
adverse event treatment, as well as a stated method or assumptions for determining the resource 
use and/or costs of adverse events. Studies were excluded if they presented clinical guidelines or 
were not original research.  Conference abstracts were excluded as the information within them 
was too limited for the purposes of this review.    
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The following electronic databases were searched to identify relevant articles published in 
English from January 1999 to September 2009: Medline, EMBASE, PubMed, EBM Reviews, 
CINAHL, Cochrane Library, Business Source Premier, Academic Search Premier, Econlit, NHS 
EED, York HTA, ASCO, and the TUFTS CEA Registry.   A search strategy was developed for 
each database using MESH headings (neoplasms, drug therapy, antineoplastic agents, drug 
toxicity, adverse effect, costs and cost analysis, cost benefit analysis, economics, length of stay, 
health resources), and relevant keywords (carcinoma, chemotherapy, adverse event, adverse 
reaction, toxicity, side effect, complication, undesired effect, cost, resource, hospitalisation).  
The search strategies for Medline, NHS EED and York HTA are provided in Online Resource 1. 
Titles and abstracts of the retrieved citations were screened to identify potentially eligible papers.  
Final assessment of eligibility was based on review of full text articles.  Additional papers 
identified from personal files and the reference lists of included papers were hand searched.  
Assessment of eligibility was completed by one reviewer for all citations.  For studies where 
eligibility was unclear, a second opinion was sought.   
Study quality was assessed for all eligible articles using the checklist developed by Graves [25].  
This checklist covers four aspects of study quality, primarily related to costing; costing issues, 
methods to determine quantities of resources used, valuing of resources and data reporting [25, 
26].  Papers were scored from zero to twelve based on the number of criteria which were met.   
Data extraction was completed by one reviewer for all articles, using the NHS EED annotated 
abstract template (http://www.crd.york.ac.uk/CRDWeb/AboutNHSEED.asp).  For the primary 
areas of interest, information was extracted on how adverse events were identified for inclusion 
in the model, whether or not dose modifications were considered, whether the quality of life 
impact of adverse events were included, and whether multiple adverse events (either over time or 
consecutively) were considered.   
3. Results 
The search yielded 4985 citations, with 26 eligible articles identified which described the use of 
economic models including methods or assumptions for resource use and/or the costs of adverse 
events associated with antineoplastic drugs.  Figure I presents a flow chart of study selection.   
Table I(a-f) provide the details of each study included in the review.  The papers were either 
designed to determine the costs and effectiveness of antineoplastic therapy (n=16) or the costs of 
a specific treatment for an adverse event (n=10).  The aims of these types of studies results in 
different methodologies and complexities.  However, as both provide different and important 
approaches to answering the questions relevant to this review, it was decided to include both 
study types, but to consider them separately.   
9 
 
Table II summarises the characteristics of the included studies.  Generally studies were of 
moderate quality, with a mean Graves score of seven and a range of three to ten (Table 1a-f).  
Six studies [19] [27] [28] [29] [30] [31] included multiple cancer types, with the remaining 
focussing on a specific cancer, the most common being breast cancer (12 studies).  Over half of 
the studies were based in the United States, with no studies from Australia or New Zealand.   
3.1 General model design 
Table III shows the modelling methods used by the included studies.  Cost effectiveness analyses 
of antineoplastic treatments primarily used Markov models, while decision trees were used in 
studies of the costs of treating adverse events.  Eighty five per cent of studies used a cost-
effectiveness or cost-consequence analysis.  The perspective taken was classified according to 
each study’s stated methods. Based on the costs included in the models, the three studies with 
unspecified perspective appear to have used a societal perspective in two cases [32] [33] and a 
hospital perspective in the other [34].     
3.2 Adverse event selection 
The 26 studies examined 21 different adverse events.  Eleven studies [32] [35] [28] [36] [37] [27] 
[31] [29] [30] [38] [39], mostly adverse event treatment studies, considered a single adverse 
event.  Of the remaining studies, nine [33, 34, 40-46]  included between two and five adverse 
events, while six [47-52] examined more than five, with 15 being the most adverse events costed 
in a single study [52].   
A number of studies (n=6) did not specify on what basis specific adverse events were selected 
for inclusion in the models.  Five studies [33, 38, 41-43] cited as a reason the presence of a 
significant difference (based on various definitions) in incidence rates of the event between 
different treatment arms in the literature.  Other reasons included a significant incidence in any 
treatment arm (usually at the 1% or 5% level) [41, 42], potential to impact on cost [45, 47, 49, 
52], or the potential to impact on patient quality of life [51].  Twenty studies included any grade 
of the event, while six [34, 41, 45, 47, 49, 52] restricted inclusion to only grade III/IV events 
(high cost/low volume events) or those resulting in hospitalisation.  
3.3 Dose modifications 
The impact of adverse events on the individual’s dose of antineoplastic therapy was specifically 
examined in five studies [41-43, 49, 52], all of which were evaluations of costs and effectiveness 
of antineoplastic drugs, with access to primary data regarding dose modifications during 
treatment.  This allowed researchers to include the actual dose received in the models. An 
additional five antineoplastic drug evaluations [39, 44, 45, 47, 51] indirectly examined the 
impact of dose modifications on total dose received by using average dose given from clinical 
trials, which should have included patients who had dose reductions or delays.  The remaining 
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six antineoplastic drug evaluations and all of the adverse event treatment studies assumed 
patients received 100% of the planned dose, regardless of the experience of adverse events.  In 
one study this was justified as being a conservative estimate of antineoplastic therapy cost [48].   
While early cessation of antineoplastic therapy was sometimes considered in terms of the amount 
of drug delivered, the impact of dose reduction and delays on survival was not.  Two studies, 
both based on the same neutropenia treatment model, included the scenario where improved 
adverse event management resulted in lower probability of receiving less than 85% of relative 
dose intensity, with resulting long-term survival benefits [36, 37].  In this model, the impact of 
relative dose intensity on long term survival was modelling using a Markov process in which the 
patient was followed until death [36, 37].  Long term survival was modelled as a function of 
patient’s age, cancer stage, and relative dose intensity (RDI) [36, 37].  Inputs for the proportion 
of patients who received less than 85% RDI, and the associated relative risk of death for those 
with an RDI <85% (compared to those with over 85%) were based on literature [36, 37].   
3.4 Adverse events and quality of life 
Measurements of quality of life for various states of cancer and cancer treatment were used in 18 
of the 26 studies (six adverse event treatment studies and 12 antineoplastic drug evaluations, see 
Table 1a-f).  Thirteen of these studies included a utility decrement associated with antineoplastic 
drug adverse events (six adverse event treatment studies and seven antineoplastic drug 
evaluations), and thus had the potential to calculate a cost per quality-adjusted life year (QALY).  
Some of these estimates included unique decrements for adverse events at different grades, or 
requiring different treatment, such as hospitalisation compared to out-patient management, but 
others included a common estimate for the adverse event that was not related to grade or 
treatment. 
Utility estimates for cancer and antineoplastic therapy health states were usually obtained from 
previous published studies in the same or similar clinical areas.  In contrast a number of utilities 
for adverse event health states were based on assumptions, rather than empirical evidence [34, 
46, 53].  For example, Lidgren et al simply reduced the utility value by 50% for six months in 
those experiencing symptomatic heart failure [46].   
3.5 Multiple adverse events 
While most models (n=14) allowed for people experiencing the same event multiple times during 
a period of antineoplastic therapy, only two studies [36, 37] (both adverse event treatment 
evaluations) specifically considered multiple events over time.  These studies, both based on the 
same febrile neutropenia treatment model, added the cost of subsequent care for febrile 
neutropenia to the cost of initial hospitalisation.  This was based on the assumption that having 
experienced one episode of febrile neutropenia, an individual is at increased risk of developing 
febrile neutropenia in the future [36, 37].     
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In two studies, models were developed which allowed for multiple events to occur at the same 
time, (one antineoplastic drug evaluation and one adverse event treatment evaluation).  Touchette 
et al (2006) modelled febrile neutropenia, anaemia and thrombocytopenia, and allowed for any 
combination of the three to be experienced in each cycle of a Markov model [40].  The costs and 
incidences of adverse events were averaged using a simple decision tree prior to being entered 
into the model [40].  However, the incidence and cost of each adverse event do not appear to 
differ based on the combination of events experienced. 
Delea et al [48] created a model in which health states were characterised by all combinations of 
adverse events.   The model included endometrial cancer, venous thromboembolism, myocardial 
infarction, unstable angina, heart failure, hip fracture, other fractures, arthralgia, and 
hypercholesterolemia [48].  Again, whilst the model allows for multiple adverse events to be 
experienced within a cycle, a simple additive model was used and as such the incidence and cost 
of each adverse event do not appear to have changed with the experience of multiple events. 
3.6 Overall 
No studies included all of the concepts of interest in their models; three studies included none of 
the concepts of interest in their models [31, 32, 35].  Most commonly included were the potential 
for an individual to experience the same event multiple times during the time horizon, and the 
impact of adverse events on patient quality of life. 
The two studies which included the most factors were those by Danova [36] and Lui [37].  Both 
studies used the same model for management of neutropenia using granulocyte colony-
stimulating factors (G-CSFs) in women with breast cancer [36, 37].  The model includes the 
impact of dose modifications on survival, the impact of neutropenia and its treatment on quality 
of life, and the potential for one episode of neutropenia to increase risk of multiple future 
episodes of neutropenia [36, 37].  As this was a model of neutropenia management, the cost of 
chemotherapy was assumed to be the same in both arms [36, 37].  This means that the influence 
of dose modifications on the total cost of chemotherapy is not accounted for, and may bias the 
results.  However, this model provides an example of how many of the important components of 
antineoplastic drug related adverse events can be incorporated into a cost effectiveness model.   
4. Discussion 
This review of the literature identified two types of economic studies which considered the costs 
of antineoplastic drug related adverse events; cost effectiveness analyses of antineoplastic 
treatments, and assessments of the costs or cost effectiveness of treatments for antineoplastic 
drug related adverse events.  Whilst there was variation across the studies in terms of methods 
used, a number of elements were consistent.  Most studies were cost effectiveness analyses 
undertaken from a health care system or hospital perspective, with only direct costs included.  
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Selection of adverse events for inclusion in models was based on incidence, cost or impact on 
quality of life.     
A high proportion of studies of breast cancer were included in the review.  This may reflect both 
a high incidence of this cancer generally, as well as a number of advances in systemic treatments 
made over the last ten years, many of which would have required economic evaluation for 
registration.   
The adverse events related to antineoplastic therapy are complex, and their consideration in 
economic evaluation is vital to ensuring accurate models are developed.  Current modelling 
techniques have a number of limitations which restrict our understanding of the true impact of 
adverse events on antineoplastic therapy cost effectiveness.  The results of this review suggest 
that many published models which include information regarding adverse events associated with 
antineoplastic therapy underestimate the incidence, costs and flow on effects of adverse events.  
In considering the issues of adverse event selection, dose modifications, quality of life and 
multiple adverse events, the results of this review provide an opportunity to present 
recommendations for the modelling of adverse events in antineoplastic therapy cost effectiveness 
studies. These recommendations have been presented as broad statements, as they are likely to be 
new considerations for modellers, and to require additional complexity and data in the models.  
However, they provide a starting point for the inclusion of all relevant impacts of adverse events 
on the costs and outcomes of antineoplastic drug therapy. 
4.1 Existing comparisons of adverse event models in antineoplastic therapy economic 
evaluations  
Existing reviews of adverse events in economic evaluations of antineoplastic therapy report 
similar results to those of this review. 
An NHS Health Technology Assessment reviewed economic evidence from fours studies of 
topotecan, doxorubicin and paclitaxel for ovarian cancer [54].  The four eligible studies included 
in the review used similar clinical evidence in their estimates of chemotherapy effectiveness, 
supplemented with estimates of resource use and costs from sources such as expert opinion, 
patient questionnaires and practice audits [54].  The review concluded that different model 
assumptions about adverse event management had the potential to both over-estimate costs 
through the inclusion of specialised treatment of high volume / low cost events, and under-
estimate chemotherapy adverse event incidence and costs through assumptions regarding 
multiple hospital admissions per cycle [54]. 
An economic evaluation of erythropoietin agents for the treatment of chemotherapy related 
anaemia provided estimates of the cost of anaemia when treated using a specified clinical 
pathway, modelled in a variety of ways and by a variety of people [55].  The different models 
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produced marked variations in results, with a range of between £190,000 and £9,000 per Quality 
Adjusted Life Year (QALY) gained [55].  This variation in results highlights the influence model 
design and assumptions can have on the outcomes of economic evaluation.   
Finally, a number of cost of illness (COI) studies have examined the costs associated with 
antineoplastic drug induced neutropenia, diarrhoea, anaemia and infusion reactions.  Many of 
these used methods such as retrospective surveys or cohort record reviews to build a bottom up 
estimate of the costs of specific adverse events [56-62].  Alternatively, some studies have utilised 
the information available from hospital and health insurance databases to determine the 
additional cost of healthcare attributable to treating a specific adverse event [63, 64].  Again, 
different model inputs resulted in significant variation in outcomes.   
4.2 Adverse event selection  
The selection criteria used to identify which adverse events to include in models may lead to 
under-estimation of the base rate of adverse events.  While the inclusion of only events with rates 
which differ between arms may not have an impact on the incremental cost effectiveness ratio 
for particular antineoplastic drug alternatives, the overall cost of adverse events (and therefore its 
impact on the relevant budget) may be higher than that implied by the results.  This influences 
whether the alternative interventions are considered cost effective at an acceptable threshold 
level.  The importance of this will depend on the decision making context that the evaluation is 
considered within. 
Similarly, adverse events which are considered to be low cost or low severity, may be excluded 
from the analysis.  While a low incidence of adverse events may not influence cost effectiveness, 
high rates may have a significant impact on overall costs.  This pattern of high incidence of low-
grade events can be seen in the new class of biological targeted agents such as cetuximab for 
colorectal cancer.  The pivotal study of cetuximab found 88% of patients experienced a rash, 
including 76.8% at the less serious grade I or II [65].  The economic analysis of this study 
excluded any adverse events less than grade III severity, as they were not thought to contribute 
significantly to resource use, despite occurring at any grade in only 16% of individuals in the 
control arm [66].   
A non-significant difference in incidence between treatment arms for a specific adverse event 
does not necessarily indicate that there is no difference in global adverse event profiles between 
treatment arms in terms of the overall toxicity profile.  By assuming conditional independence of 
the frequency of events, the potential for the sum of adverse events to differ between treatments 
is removed.   
The inclusion of all relevant adverse events in models of antineoplastic therapy cost 
effectiveness is consistent with recommendations for the modelling of adverse effects for all 
health interventions [67] [68].  However, including all adverse events will require additional 
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complexity in the model, and additional data to populate these components of the model.  The 
use of Markov modelling techniques may provide a way to address this additional complexity 
[6], and clinical trials would be the most likely source of additional information about the costs 
and consequences of adverse events.  Further work is required to identify how the inclusion of all 
adverse events will impact results. 
Recommendation: All relevant adverse events which are associated with antineoplastic drug 
treatment should be included in models of antineoplastic therapy cost effectiveness. 
4.3 Dose modifications  
While some studies did consider the impact that dose modifications would have on the total dose 
of antineoplastic drugs received, many assumed all patients received one hundred per cent of the 
recommended dose.  In the context of a cost effectiveness evaluation, this would result in an 
overestimation of the costs, as some cost savings are ignored.  In the area of cancer treatments, 
where new antineoplastic drugs are increasingly expensive, the cost of purchasing the drugs may 
be a significant contributor to costs, and therefore overall cost-effectiveness.  Intravenous 
treatments may have the additional complexity of wastage, as once a vial is opened it often must 
be used immediately or discarded.  When a patient is on a reduced dose they may not receive the 
whole vial, but costs in the model will still need to reflect that a full vial has been used.    
Clinical trial reports may provide details of the dose modifications and drug wastage during the 
trial.  Information on planned dose, dose dispensed, dose received, and reasons for dose 
modifications would be ideal for economic modelling. Where this information is not available, 
data from observational studies, such as information regarding the frequency of dose 
modifications may be used to provide inputs to the model regarding the incidence of dose 
modifications.  The potential cost savings associated with dose modifications can be estimated 
using the input price and incorporated into the estimates of product cost per treatment arm.  
Practice guidelines for the administration of antineoplastic drugs may provide some guidance to 
the modelling of product wastage.  
Recommendation:  The cost savings resulting from dose modifications due to adverse events 
should be accounted for in models of antineoplastic therapy cost effectiveness. 
Only two studies considered the impact of dose modifications on survival.  With survival often 
the primary outcome of effectiveness in cost effectiveness studies, changes to it as a result of 
adverse events and dose reductions could affect the cost effectiveness ratio, particularly if 
adverse events occur unevenly across treatment arms.  As identified in this review, many 
economic evaluations of the cost effectiveness of antineoplastic therapy select adverse events for 
inclusion on the basis of there being a significant difference in incidence between treatments. 
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It is interesting that although there is a body of literature which examines the cost effectiveness 
of treatments for neutropenia in relation to their ability to maintain chemotherapy dose intensity 
[69], there appears to be little transfer of this information into models of antineoplastic drug cost 
effectiveness, despite many of these models including neutropenia and the costs of its 
management.   
There is relatively little evidence available for the influence of dose modifications on the 
effectiveness of specific antineoplastic drug treatments.  This makes inclusion of these outcomes 
within the model difficult, as no data are available to populate the model.  Economic models 
based on the results of a clinical trial which has followed patients to death will have implicitly 
considered the impact of dose modifications on survival. However, where follow up is not 
complete or data are insufficient, the growing body of evidence across a range of chemotherapy 
treatments that receiving less chemotherapy reduces efficacy could be used within a sensitivity 
analysis of the estimated antineoplastic drug efficacy.  This would allow the potential impact of 
uncertainty around the estimates of antineoplastic drug efficacy to be tested.     
Recommendation:  The impact of dose modifications due to adverse events on the outcomes of 
antineoplastic therapy should be considered and included in the sensitivity analysis of models of 
cost effectiveness. 
4.4 Adverse events and quality of life  
The impact on quality of life of cancer and antineoplastic therapy are generally well considered 
in cost effectiveness studies of antineoplastic drugs and new adverse event treatments.  It is less 
common for the additional utility decrements associated with adverse events to be included, and 
these are often difficult to identify [70].  Part of the difficulty in including additional utility 
decrements (or improvements) associated with adverse events is how these should be considered 
in relation to the quality of life impacts of having cancer and undergoing antineoplastic drug 
therapy.  While there are studies which have estimated specific utility decrements for adverse 
events independent of treatment [71], in many cases the decrement associated with antineoplastic 
treatment may include a component related to adverse events.  If this was the case, the addition 
of a decrement associated with an adverse event may lead to double counting [8].  It is therefore 
important that the original source of utility scores and the basis for the applied utility weights for 
both antineoplastic drugs and adverse events be understood before they are incorporated into an 
economic evaluation. In cases where adequate evidence to populate the specific utility 
decrements associated with adverse events are not available, utility measures for the experience 




Recommendation: The impact of adverse events on quality of life should be considered, and 
included in models of antineoplastic therapy cost effectiveness, where adequate evidence to 
populate these components is available. 
4.5 Multiple adverse events  
As the usual sources of information about the incidence of adverse events, clinical trials, report 
events separately and very rarely provide information about patterns of multiple adverse events.  
Thus it is not surprising that models of antineoplastic therapy include each adverse event as an 
independent event. However this is not reflective of real life. Multiple simultaneous adverse 
events are complex to model.  It is often unclear which adverse event has resulted in which 
resource use (eg hospitalisation) or outcomes (eg reduced quality of life) and therefore the 
impact on cost effectiveness is difficult to gauge.  The use of clinical trial data to examine 
patterns of multiple adverse events would provide an ideal resource for the modelling of multiple 
adverse events.   
In relation to the influence of multiple events on utility, there has been significant interest in 
developing quantitative methods to account for comorbidities when assessing health 
interventions [72].  In studies of cancer, adverse events are commonly considered individually, 
however the high prevalence of simultaneous adverse events is increasingly recognised as 
important [73].   Whilst direct elicitation of the utility of these simultaneous events through 
techniques such as standard gamble and time trade-off are possible, the time, resources and 
respondent burden to collect utilities for more than a simultaneous events makes conducting 
these assessments impractical [73]. Modelling approaches have therefore been investigated.  The 
original additive approach to modelling combined utilities has been identified as overly 
simplistic, and techniques such as multiplicative and minimum modelling are now being studied 
and used [72, 73].      
Recommendation: Further research is required to allow the consideration of concurrent or 
consecutive multiple adverse events in models of antineoplastic therapy cost effectiveness. 
4.6 Limitations of the review  
Whilst a systematic review of the literature was undertaken, there may be published economic 
models incorporating antineoplastic drug related adverse events which were missed.  The 
relatively small proportion of economic evaluations of antineoplastic drugs which were eligible 
for inclusion in the review appears to be a factor of the inclusion criteria requiring papers to 
present the methods for determining the resource use and/or cost of adverse events.  The 
exclusion of those papers which simply report a cost without justification allows this review to 
focus on the methods used to include adverse events, but may result in it not be representative of 
all studies of antineoplastic drug cost effectiveness.  
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In addition, the exclusion of papers in languages other than English and conference abstracts 
may have biased the types of models which were included.  Similarly, given that many economic 
evaluations are conducted for the purpose of policy decision making, there may be economic 
evaluations of antineoplastic agents which have been developed, but are not available in the 
peer-reviewed economic literature.  These evaluations may differ systematically from those 
identified in this review, which may have biased the results. 
A final potential limitation of the search strategy is that it identified two distinct types of 
economic evaluations – those assessing the cost effectiveness of antineoplastic drugs, and those 
assessing the cost effectiveness of adverse event treatments.  While both of these are appropriate 
to answer the questions posed by this review, separate search strategies may have resulted in 
more efficient identification of eligible papers in these two areas.  
For many of the economic evaluations identified, particularly those assessing the cost 
effectiveness of antineoplastic drugs, the costs of adverse events were not the primary aim of the 
analysis.  Conducting an economic evaluation is a difficult and time consuming task, the aim of 
which is to provide information to decision makers.  Despite model builders’ best efforts, the 
results of analysis are not designed to represent real life, but rather to provide information about 
the likely outcomes of a decision.  This means that while there may be many aspects of the 
disease pathway, treatment choices, and patient characteristics which may influence the 
outcomes of a decision, they cannot all be incorporated into a model.  It may be that for some of 
the models included in this review detailed modelling of adverse events was a lower priority than 
evaluations of other areas of the treatment pathway. 
5.  Conclusion 
A number of components are important to the rigorous modelling of antineoplastic drug adverse 
events, including the selection of all relevant events, the impact of adverse events on 
antineoplastic drug dose, cancer outcomes and quality of life, and the consideration of multiple 
adverse events.  This literature review systematically searched for all relevant articles which 
included adverse events in a model of costs and consequences of antineoplastic drugs. There 
were no models which incorporated all of components discussed above.  Two models addressed 
all but one of the issues, and these models provide an indication of how adverse events can be 
incorporated into economic evaluations in a rigorous way.   Given that there were at least two 
examples of papers which considered each issue in their model development, it would appear 
that it is possible to build models of antineoplastic drug adverse events which consider all of 
these issues. 
The adverse events related to antineoplastic therapy are complex; however, their consideration in 
economic evaluation is vital to ensuring accurate models are developed.  Current modelling 
techniques have a number of limitations, which restrict our understanding of the true impact of 
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adverse events on antineoplastic drug cost effectiveness, and it appears that many published 
models may under estimate the incidence, cost and flow on effects of adverse events.   
Rigorous modelling of antineoplastic drug adverse events will require the development of more 
complex models and the availability of additional data.  Clinical trials are in a unique position to 
collect data on many aspects of antineoplastic drug adverse events. However, the inclusion of 
questions relating to economic evaluation needs to be considered in the study design phase.  In 
the absence of trial data, or for information relating to the experience of antineoplastic drug 
adverse events outside the trial setting, data from observational or administrative datasets can 
contribute to economic evaluations.  Again, careful consideration of the data available, the 
economic question being posed and the implications of using observational data is required. 
Given that modelling adverse events with appropriate consideration of: the inclusion of all 
events, dose modifications, quality of life and multiple events appears feasible, future models of 
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Table I(a) Adverse event treatment studies of neutropenia 
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Table I(b) Adverse event treatment studies of anaemia, thrombocytopenia and multiple adverse events 
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AE - adverse event, CEA - cost effectiveness analysis, CMA - cost minimisation analysis, CUA - cost utility analysis, EPO – erythropoietin, Hb – haemoglobin, RBCT – red blood cell 





Table I(c) Adverse event treatment studies of nausea and vomiting 
Reference Cancer type, 






























perspective.   









































No N/A - only 
considered one 
AE 





Table I(d) Antineoplastic cost effectiveness studies of early or primary breast cancer 
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AE - adverse event, CEA - cost effectiveness analysis, CMA - cost minimisation analysis, CUA - cost utility analysis, MI – myocardial infarction, VTE – venous thromboembolism, 









Table I(e) Antineoplastic cost effectiveness studies of metastatic or advanced breast cancer 
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Table I(f) Antineoplastic cost effectiveness studies of cancers other than breast 
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AE - adverse event, CEA - cost effectiveness analysis, CMA - cost minimisation analysis, CUA - cost utility analysis, FOLFIRI – folinic acid fluorouracil and irinotecan, FOLFOX – folinic acid 




Table II Characteristics of included studies 








n =  16 10 26 
Cancers    
Breast 10 2 12 
Any 0 6 6 
Colorectal 2 0 2 
Ovarian 2 1 3 
Lung 1 1 2 
Head and neck 1 0 1 
    
Cancer stage    
Any stage / stage not specified 0 7 7 
Locally advanced / metastatic 9 1 10 
Early 7 2 9 
    
Country    
Europe 5 4 9 
United States of America 8 6 14 
United Kingdom 2 0 2 
Canada 1 0 1 
Asia 0 0 0 
    
Industry involvement    
Yes – funded or authorship 11 8 19 






Table III Modelling methods used by included studies 








n =  16 10 26 
Economic analysis    
Cost effectiveness / consequence 11 7 18 
Total cost 1 0 1 
Cost minimisation 1 2 3 
Cost utility 1 0 1 
Cost of illness 0 0 0 
Cost benefit 0 0 0 
Cost effectiveness and cost utility 2 1 3 
    
Perspective    
Health care system / hospital 6 7 13 
Third party payer 4 0 4 
Society 4 2 6 
Not specified 2 1 3 
    
Model    
Decision tree 2 7 9 
Markov model 11 2 13 
Other models 3 1 4 
    
Costs included    
Direct 12 7 19 
Indirect 0 0 0 
Direct and indirect 4 3 7 
    
Sensitivity analysis    
Univariate 15 8 23 
Multivariate 6 2 8 










identified by search of multiple databases using key search terms for 
antineoplastic drugs, side effects, and cost, followed by hand searches of 
reference lists 
479 full text articles 
for assessment 
26 eligible articles 
included in review 
453 articles excluded: 
  - 219 no cost of AE calculation or  
     information 
  - 84  not original research 
  - 51 not cancer, or non-solid cancer 
  - 25 not antineoplastic drug 
  - 74 other reasons, eg model 
    development 
